Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-low-dose decitabine in myelodysplastic syndromes
ChiCTR-IPR-16008100Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of decitabine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Started Mar 2016; status: recruiting.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on ChiCTR-IPR-16008100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008100.